Bakuchiol-lipid nanoparticle for the treatment of atopic dermatitis
- 주제(키워드) Atopic dermatitis , bakuchiol , lipid nanoparticles , topical delivery , anti- inflammation
- 주제(DDC) 615.1
- 발행기관 아주대학교 일반대학원
- 지도교수 Tae-Jong Yoon
- 발행년도 2026
- 학위수여년월 2026. 8
- 학위명 박사
- 학과 및 전공 일반대학원 약학과
- 실제URI http://www.dcollection.net/handler/ajou/000000036638
- 본문언어 영어
- 저작권 아주대학교 논문은 저작권에 의해 보호받습니다.
초록/요약
Bakuchiol-lipid nanoparticles for the treatment of atopic dermatitis Hyung-Goo Kim Department of Pharmacy Graduate School Ajou University Advised by Professor Tae-Jong Yoon Nanoparticles have been extensively studied by many researchers due to their various advantages. However, most nanoparticles have shown limitations in terms of toxicity and biocompatibility. In contrast, lipid nanoparticles （LNPs） are gaining significant attention because of their safety, biocompatibility, and high bioavailability. When developing these lipid nanoparticles, factors such as encapsulation efficiency, stability, cellular uptake, skin permeability, and both in vivo and in vitro safety must be carefully considered. In this thesis, I evaluated the therapeutic effects of lipid nanoparticles on atopic dermatitis while considering the aforementioned factors. Atopic dermatitis is a chronic inflammatory disease characterized by persistent pruritus and skin barrier dysfunction. While corticosteroids are the most commonly used treatment, their long-term use is limited by side effects such as skin atrophy. However, bakuchiol, a plant-derived compound, is free from these side effects and is expected to alleviate atopic dermatitis through various biological activities, including anti-inflammatory effects. To overcome the hydrophobicity and low skin permeability of bakuchiol, I introduced lipid nanoparticles, through which I confirmed the reduction of inflammation, relief of pruritus, and improvement of the skin barrier in atopic dermatitis. Additionally, I verified that this platform inhibits post-inflammatory hyperpigmentation （PIH）, a characteristic feature of chronic inflammatory dermatitis.
more목차
1.1 Abstract 1
1.2 Introduction 2
1.3 Materials and methods 6
1.3.1 Materials 6
1.3.2 Preparation and Characterization of BKC-loaded LNPs 7
1.3.3 Preparation of RITC-labeled LNPs for Tracing 8
1.3.4 Cell Culture 8
1.3.5 Flow cytometric analysis 8
1.3.6 ELISA analysis for Pro-inflammatory Cytokine Quantification 9
1.3.7 Immunofluorescence for NF-κB Translocation 9
1.3.8 Determination of Intracellular Melanin Contents 10
1.3.9 RNA Extraction and Quantitative Real-Time PCR (qRT-PCR) 10
1.3.10 In Vitro Cytotoxicity assay 11
1.3.11 In Vitro Release and Ex Vivo Skin Permeation Assay 11
1.3.12 Animals and Ethical Statement 12
1.3.13 Induction of AD-like Skin Lesions and In Vivo Treatment 12
1.3.14 High-Performance Liquid Chromatography (HPLC) Analysis 13
1.3.15 Statistical analysis 13
1.4 Result 14
1.4.1 Preparation and Physicochemical characterization of BKC-LNPs 14
1.4.2 Enhanced Transdermal Permeation of BKC-LNPs 19
1.4.3 Establishment of the In Vitro Macrophage Inflammation Model 20
1.4.4 In Vitro Anti-inflammatory Efficacy and NF-κB Pathway Inhibition 21
1.4.5 In Vivo Amelioration of DNCB-Induced AD Lesions 26
1.4.6 Disruption of the Itch-Scratch Cycle and Restoration of Epidermal Barrier Integrity 30
1.4.7 In Vitro Suppression of Melanogenesis for Post-Inflammation Hyperpigmentation 31
1.5 Discussion 35
1.6 Conclusion 38
1.7 Reference 39
